Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Gilead Sciences
AstraZeneca
AstraZeneca
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
University of Miami
Eli Lilly and Company
Sichuan Baili Pharmaceutical Co., Ltd.
SOLTI Breast Cancer Research Group
Dana-Farber Cancer Institute
Jonsson Comprehensive Cancer Center
Sichuan Baili Pharmaceutical Co., Ltd.
Fudan University
UNICANCER
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Sun Yat-sen University
University of Ulm